New combo therapy aims to shrink eye tumors before radiation

NCT ID NCT05893654

ENROLLING_BY_INVITATION Disease control Sponsor: Hospital das Clínicas de Ribeirão Preto Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This early-phase trial tests whether injecting the chemotherapy drug melphalan directly into the eye's blood vessels can shrink large uveal melanomas (eye cancers) enough to then treat them with radiation. Ten adults with tumors at least 8 mm thick will receive the chemo injection followed by a radioactive plaque placed on the eye. Researchers will monitor safety (retinal function) and tumor shrinkage over 6 months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Melphalan (chemotherapy drug)
What this could lead to: If successful, this approach could shrink large eye tumors enough to allow effective radiation therapy, potentially saving more eyes from removal.
What could go wrong: This is a very early, small trial (10 people) focused on safety. The chemo may cause retinal toxicity, and it is unknown if the combination will work better than standard treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHOROIDAL MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malignant choroid melanoma melanoma uveal melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

UVEAL MELANOMA

Contacts and locations

Locations

Hospital das Clinicas da Faculdade de Medicina de Ribeirao Preto - USP

Ribeirão Preto, São Paulo, 14040-906, Brazil

More trials for these conditions

Other studies related to the condition(s) this trial covers.